XML 31 R22.htm IDEA: XBRL DOCUMENT v3.23.2
MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES (Tables)
 6 Months Ended
Jun. 30, 2023
Novartis Institutes for BioMedical Research, Inc.  
Research and Development Arrangement, Contract to Perform for Others [Line Items]  
Revenues Recognized under Agreement Revenues recognized under the agreement were as follows (in thousands):
Three Months Ended
June 30,		Six Months Ended
June 30,
2023202220232022
Revenue related to Novartis agreement:
Recognition of upfront license fee$1,872 $8,622 $9,568 $15,640 
Research services554 2,306 2,613 4,183 
Total$2,426 $10,928 $12,181 $19,823 
Biogen MA, Inc.  
Research and Development Arrangement, Contract to Perform for Others [Line Items]  
Revenues Recognized under Agreement
Revenues recognized under the agreement were as follows (in thousands):
Three Months Ended
June 30,		Six Months Ended
June 30,
2023202220232022
Revenue related to Biogen agreement:
Recognition of license and other fixed consideration$1,535 $7,306 $132,165 $14,612 
Cost-sharing payments for research services, net variable consideration669 2,746 2,341 6,633 
Total$2,204 $10,052 $134,506 $21,245 
Kite Pharma, Inc.  
Research and Development Arrangement, Contract to Perform for Others [Line Items]  
Revenues Recognized under Agreement Revenues recognized under the agreement were as follows (in thousands):
Three Months Ended
June 30,		Six Months Ended
June 30,
2023202220232022
Revenue related to Kite agreement:
Recognition of license fee fixed consideration$1,110 $6,227 $12,550 $12,386 
Research services variable consideration121 107 989 256 
Total$1,231 $6,334 $13,539 $12,642